Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4- acetic acid (DMXAA): Increased tumor vascular permeability

International Journal of Cancer

Volumn 116, Issue 2, 2005, Pages 322-326

  Zhao, Liangli ^a   Ching, Lai Ming ^a   Kestell, Philip ^a   Kelland, Lloyd R ^b   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antivascular; Serotonin; Tumor necrosis factor; Vascular permeability

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; EVANS BLUE; HOE 33342; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; STAINING; THROMBOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; COLONIC NEOPLASMS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XANTHONES;

EID: 22044437369     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21005     Document Type: Article

References (42)

1. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-7.
2. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
3. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
4. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Haibert GW, Kestell P, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50.
5. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR. Effects of 5, 6-dimethylxanthenone- 4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
6. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5, 6-dimethylxanthenone-4- acetic acid. Br J Cancer 2002;86:1937-42.
7. Ching LM, Zwain S, Baguley CC. Relationship between tumour enclothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90:906-10.
8. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The morphological effects of the anti-tumor agents flavone acetic acid and 5, 6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology 1994;26:161-9.
9. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996;56:4264-6.
10. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999;43:1111-23.
11. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5, 6-dimethylxanthenone-4- acetic acid. Br J Cancer 1999;80:716-23.
12. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5, 6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999;59:633-8.
13. Ferrero E, Villa A, Ferrero ME, Toninelli E, Bender JR, Pardi R, Zocchi MR. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996;56:3211-5.
14. Mark KS, Miller DW. Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. Life Sci 1999;64:1941-53.
15. Aicher KP, Dupon JW, White DL, Aukerman SL, Moseley ME, Juster R, Rosenau W, Winkelhake JL, Brasch RC. Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Res 1990;50:7376-81.
16. Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001;281:C1173-9.
17. Browne WL, Wilson WR, Baguley BC, Ching LM. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5.6-dimethylxanthenone-4-acetic acid. Anticancer Res 1998;18:4409-13.
18. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-92.
19. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997;9:55-60.
20. Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surroeate marker for the action of antivascular agents. Clin Chim Acta 2001;314:159-66.
21. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA. Potential antitumor agents: 61, structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991;34:217-22.
22. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 2000;6:2829-34.
23. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 1989;81:1005-13.
24. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 1989;25:263-9.
25. Zhao L, Ching LM, Kestell P, Baguley BC. The antitumour activity of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002;87:465-70.
26. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999;59:3304-7.
27. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5, 6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204.
28. Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2, 2′-(1,4-diaminobutane) bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4- acetic acid. Cancer Res 2000;60:4582-8.
29. Hofmann S, Grasberger H, Jung P, Bidlingmaier M, Vlotides J, Janssen OE, Landgraf R. The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Eur J Med Res 2002;7:171-6.
30. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996;183:1981-6.
31. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76(Suppl 1):S60-80.
32. Schmiedl U, Ogan M, Paajanen H, Marotti M, Crooks LE, Brito AC, Brasch RC. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 1987;162(1 Pt 1):205-10.
33. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5, 6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-6.
34. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52.
35. Kelland LR, Rowlinson-Busza G, Griffiths-Johnson D, Hadfield S, McKay J, Baguley BC, Courtenay-Luck N. Single agent activity and potentiation of the antitumour activity of paclitaxel and gemcitabine with the vascular targeting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in human tumour xenografts. Proc Am Assoc Cancer Res 2003;44:693.
36. Chung F, Wang LC, Kestell P, Baguley BC, Ching LM. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5, 6-dimethylxanthenone-4- acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemother Pharmacol 2004;53:377-83.
37. Finlay GJ, Baguley BC. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol 2000;45:417-22.
38. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300.
39. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999;59:3998-4003.
40. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, Wolf GL, Fischman A, Boucher Y, Jain RK. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999;96:3137-42.
41. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol 1998;8:164-75.
42. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F, Jain RK. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999;59:4129-35.